Eloralintide and tirzepatide combined for weight loss in adults with obesity
Tests eloralintide with tirzepatide for weight loss in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Key facts
- Where
- Albuquerque, Arlington, Atlantis, Baltimore, Bellaire, Boston, Chapel Hill, Chicago, Covina, Dallas, Dalton, Dunwoody, Euless, Eunice, Greensboro, Honolulu, Houston, Indianapolis, Kingwood, Las Vegas, Long Island City, Los Angeles, Maitland, Memphis, Mesa, Metairie, Miami, New Haven, New York, Newport News, Norfolk, Philadelphia, Plymouth Meeting, Raleigh, Ridgeland, Rolling Hills Estates, San Antonio, San Diego, Santa Ana, Scottsdale, Shavano Park, Stockbridge, Tamarac, Tampa, Tucson, Tyler, Union City, and West Valley City, United StatesSee the 55 sites
- Phase
- Phase 3
Where in United States
- IMA Clinical Research - AlbuquerqueAlbuquerque, United StatesNo longer taking part
- Care Access - Arlington 2Arlington, United StatesNo longer taking part
- Washington Center for Weight Management and ResearchArlington, United StatesNo longer taking part
- JEM Research InstituteAtlantis, United StatesNo longer taking part
- Care Access - BaltimoreBaltimore, United StatesNo longer taking part
- Pharmasite Research, Inc.Baltimore, United StatesNo longer taking part
- JCCT - Juno Bellaire SiteBellaire, United StatesNo longer taking part
- The University of Texas Health Science Center at HoustonBellaire, United StatesNo longer taking part
- Brigham and Women's Hospital Diabetes ProgramBoston, United StatesNo longer taking part
- University of North Carolina Medical CenterChapel Hill, United StatesNo longer taking part
- IMA Clinical Research ChicagoChicago, United StatesNo longer taking part
- Valley Clinical Trials, Inc.Covina, United StatesNo longer taking part
- Cedar Health ResearchDallas, United StatesNo longer taking part
- Care Access - Dalton WalmartDalton, United StatesNo longer taking part
- Teak Research Consults - DunwoodyDunwoody, United StatesNo longer taking part
- Cedar Health Research - EulessEuless, United StatesNo longer taking part
- Care Access - EuniceEunice, United StatesNo longer taking part
- Medication ManagementGreensboro, United StatesNo longer taking part
- East-West Medical Research InstituteHonolulu, United StatesNo longer taking part
- Biopharma Informatic, LLCHouston, United StatesNo longer taking part
- Care Access - Houston - Clinical Trials Center by Walmart & Care AccessHouston, United StatesNo longer taking part
- PlanIt Research, LLCHouston, United StatesNo longer taking part
- DM Clinical Research, IndianapolisIndianapolis, United StatesNo longer taking part
- Activian Clinical ResearchKingwood, United StatesNo longer taking part
- IMA Clinical Research - Las VegasLas Vegas, United StatesNo longer taking part
- Palm Research Center SunsetLas Vegas, United StatesNo longer taking part
- NYC Research Inc.Long Island City, United StatesNo longer taking part
- Los Angeles Institute for Metabolic ResearchLos Angeles, United StatesNo longer taking part
- K2 Medical Research - MaitlandMaitland, United StatesNo longer taking part
- Clinical Neuroscience Solutions, Inc.Memphis, United StatesNo longer taking part
- Care Access - 801 South Power Road, MesaMesa, United StatesNo longer taking part
- Clinical Trials Management, LLC d/b/a Flourish ResearchMetairie, United StatesNo longer taking part
- Flourish Research - Miami, LLCMiami, United StatesNo longer taking part
- Yale University School Of MedicineNew Haven, United StatesNo longer taking part
- IMA Clinical Research - NYC MidtownNew York, United StatesNo longer taking part
- Weill Cornell Medical CollegeNew York, United StatesNo longer taking part
- Health Research of Hampton Roads, Inc.Newport News, United StatesNo longer taking part
- Eastern Virginia Medical School (EVMS) Medical GroupNorfolk, United StatesNo longer taking part
- Clinical Research of PhiladelphiaPhiladelphia, United StatesNo longer taking part
- Keystone Clinical StudiesPlymouth Meeting, United StatesNo longer taking part
- Care Access - RaleighRaleigh, United StatesNo longer taking part
- SKY Integrative Medical Center/SKYCRNGRidgeland, United StatesNo longer taking part
- Peninsula Research AssociatesRolling Hills Estates, United StatesNo longer taking part
- Clinical Trials of Texas LLCSan Antonio, United StatesNo longer taking part
- Artemis Institute for Clinical ResearchSan Diego, United StatesNo longer taking part
- Southern California Clinical ResearchSanta Ana, United StatesNo longer taking part
- Headlands Research - ScottsdaleScottsdale, United StatesNo longer taking part
- Consano Clinical Research, LLCShavano Park, United StatesNo longer taking part
- Clinical Research AtlantaStockbridge, United StatesNo longer taking part
- Care Access - TamaracTamarac, United StatesNo longer taking part
- Care Access - TampaTampa, United StatesNo longer taking part
- Tucson Clinical Research InstituteTucson, United StatesNo longer taking part
- Care Access - Tyler - Clinical Trials Center by Walmart & Care AccessTyler, United StatesNo longer taking part
- Rophe Adult and Pediatric Medicine/SKYCRNGUnion City, United StatesNo longer taking part
- Kalo Clinical ResearchWest Valley City, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07881432EU 2026-526047-34-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.Read full original descriptionShow less
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.
Inclusion: Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening; Have a BMI of ≥35 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any glucose-lowering medication within 90 days of screening.